[
  {
    "ts": null,
    "headline": "Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy",
    "summary": "Boston Scientific posts strong Q3 growth and upgrades 2025 outlook. See why BSX stock is rated Buy and what drives its leadership.",
    "url": "https://finnhub.io/api/news?id=b6c667f6690ba47cd1c8f8a83db65a71c8024219e9c79c3495d9653560223cbe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761262475,
      "headline": "Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy",
      "id": 137200210,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2204862969/image_2204862969.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Boston Scientific posts strong Q3 growth and upgrades 2025 outlook. See why BSX stock is rated Buy and what drives its leadership.",
      "url": "https://finnhub.io/api/news?id=b6c667f6690ba47cd1c8f8a83db65a71c8024219e9c79c3495d9653560223cbe"
    }
  },
  {
    "ts": null,
    "headline": "BSX Q3 Deep Dive: WATCHMAN and Electrophysiology Drive Outperformance, Guidance Raised",
    "summary": "Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q3 CY2025, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=ce9ad0b0ada241867d1d034bf3e65564d43f273b39bddc6856d14c129423b94b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761242447,
      "headline": "BSX Q3 Deep Dive: WATCHMAN and Electrophysiology Drive Outperformance, Guidance Raised",
      "id": 137216517,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q3 CY2025, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=ce9ad0b0ada241867d1d034bf3e65564d43f273b39bddc6856d14c129423b94b"
    }
  },
  {
    "ts": null,
    "headline": "WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit",
    "summary": "West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.",
    "url": "https://finnhub.io/api/news?id=4af80ee297e443f73561a960866f5e3a9431448bfafc1de3eb83a7e94bee72e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761238080,
      "headline": "WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit",
      "id": 137216518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.",
      "url": "https://finnhub.io/api/news?id=4af80ee297e443f73561a960866f5e3a9431448bfafc1de3eb83a7e94bee72e0"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific (BSX) is an Incredible Growth Stock: 3 Reasons Why",
    "summary": "Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
    "url": "https://finnhub.io/api/news?id=ceaea724e6a42bfe6291ca85075650164a179dfad52bd3fd7be2473b0ed8d49d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761237902,
      "headline": "Boston Scientific (BSX) is an Incredible Growth Stock: 3 Reasons Why",
      "id": 137216519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
      "url": "https://finnhub.io/api/news?id=ceaea724e6a42bfe6291ca85075650164a179dfad52bd3fd7be2473b0ed8d49d"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock underperforms Thursday when compared to competitors",
    "summary": "Boston Scientific Corp. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=02ec9950168a16ab8d31856f5eab61a20f5075a387c7f1395fd784603447e462",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761237360,
      "headline": "Boston Scientific Corp. stock underperforms Thursday when compared to competitors",
      "id": 137252042,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=02ec9950168a16ab8d31856f5eab61a20f5075a387c7f1395fd784603447e462"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Maintains Boston Scientific (BSX) Overweight Recommendation",
    "summary": "Wells Fargo Maintains Boston Scientific (BSX) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=bc3055887588b866815654e465b49cc785bea700d18020f18208e15d087197f4",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761236433,
      "headline": "Wells Fargo Maintains Boston Scientific (BSX) Overweight Recommendation",
      "id": 137197164,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=bc3055887588b866815654e465b49cc785bea700d18020f18208e15d087197f4"
    }
  },
  {
    "ts": null,
    "headline": "Canaccord Genuity Maintains Boston Scientific (BSX) Buy Recommendation",
    "summary": "Canaccord Genuity Maintains Boston Scientific (BSX) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=d88fb8b5e0c11827f8af10129a92a8f772ed1e99728f869844e0b0049d7bc761",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761236432,
      "headline": "Canaccord Genuity Maintains Boston Scientific (BSX) Buy Recommendation",
      "id": 137197166,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d88fb8b5e0c11827f8af10129a92a8f772ed1e99728f869844e0b0049d7bc761"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Boston Scientific (BSX) Overweight Recommendation",
    "summary": "Morgan Stanley Maintains Boston Scientific (BSX) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=d5d5af67962ef8fa2ace0fa7188190006b6fed71dd6f3e045688d5fee21de078",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761236432,
      "headline": "Morgan Stanley Maintains Boston Scientific (BSX) Overweight Recommendation",
      "id": 137197165,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d5d5af67962ef8fa2ace0fa7188190006b6fed71dd6f3e045688d5fee21de078"
    }
  },
  {
    "ts": null,
    "headline": "Truist Securities Maintains Boston Scientific (BSX) Buy Recommendation",
    "summary": "Truist Securities Maintains Boston Scientific (BSX) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=76b1d3b0d5e540daf72bdd0cd45e1ccf3a56a653d5e501d769126adc4c2d998a",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761236431,
      "headline": "Truist Securities Maintains Boston Scientific (BSX) Buy Recommendation",
      "id": 137197167,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=76b1d3b0d5e540daf72bdd0cd45e1ccf3a56a653d5e501d769126adc4c2d998a"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Boston Scientific (BSX) is a Strong Growth Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=a52060e3721753d7ff43a54acef3ea4cb8bcd88334b5e554751243f05baebe55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761227104,
      "headline": "Here's Why Boston Scientific (BSX) is a Strong Growth Stock",
      "id": 137198209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=a52060e3721753d7ff43a54acef3ea4cb8bcd88334b5e554751243f05baebe55"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific (BSX) Recently Broke Out Above the 50-Day Moving Average",
    "summary": "Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?",
    "url": "https://finnhub.io/api/news?id=1fdb72f38a8b1c6e4ae567b0298f05de47459d040bc6a9f882e8b95ff120897a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761226201,
      "headline": "Boston Scientific (BSX) Recently Broke Out Above the 50-Day Moving Average",
      "id": 137198212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?",
      "url": "https://finnhub.io/api/news?id=1fdb72f38a8b1c6e4ae567b0298f05de47459d040bc6a9f882e8b95ff120897a"
    }
  },
  {
    "ts": null,
    "headline": "Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?",
    "summary": "Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=883d6990119e549bd4ed51e381bd39fb3a3b6a13fe0a913d4c70414a6f67d259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761226201,
      "headline": "Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?",
      "id": 137198211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=883d6990119e549bd4ed51e381bd39fb3a3b6a13fe0a913d4c70414a6f67d259"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors",
    "summary": "Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?",
    "url": "https://finnhub.io/api/news?id=a655ad31a54781205f543536e3274396136412ffa2e0ecafa3e0fc5baefda5fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761226201,
      "headline": "Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors",
      "id": 137198210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?",
      "url": "https://finnhub.io/api/news?id=a655ad31a54781205f543536e3274396136412ffa2e0ecafa3e0fc5baefda5fc"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Oct 23, 2025",
    "summary": "Companies in The News Are: BSX, ISRG, BCS, CB",
    "url": "https://finnhub.io/api/news?id=465bdeffc637e6e0fc9f92bdf5e0023a938779d526f5f1e92375cff92739996f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761226080,
      "headline": "Company News for Oct 23, 2025",
      "id": 137198101,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Companies in The News Are: BSX, ISRG, BCS, CB",
      "url": "https://finnhub.io/api/news?id=465bdeffc637e6e0fc9f92bdf5e0023a938779d526f5f1e92375cff92739996f"
    }
  },
  {
    "ts": null,
    "headline": "GCC $1.25+ Bn Catheter Market Growth Trends and Forecast to 2033 Featuring Abbott, Edwards Lifesciences, BD and Co, Boston Scientific, Medtronic, Johnson & Johnson, Stryker, Teleflex",
    "summary": "The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow",
    "url": "https://finnhub.io/api/news?id=fce5d1ea8f0bddc4ec9de6a99102bb87c65387bd0a9313713100f27104bcde46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761210540,
      "headline": "GCC $1.25+ Bn Catheter Market Growth Trends and Forecast to 2033 Featuring Abbott, Edwards Lifesciences, BD and Co, Boston Scientific, Medtronic, Johnson & Johnson, Stryker, Teleflex",
      "id": 137197767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow",
      "url": "https://finnhub.io/api/news?id=fce5d1ea8f0bddc4ec9de6a99102bb87c65387bd0a9313713100f27104bcde46"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific (BSX): Earnings Jump 37%, Profit Margins Beat Bull Case Expectations",
    "summary": "Boston Scientific (BSX) delivered standout earnings growth, with profits up 18.5% per year over the last five years and a strong 37% gain in the most recent year. Net profit margins rose to 13.5% from 12% previously. Forward-looking guidance points to annual earnings growth of 16.6%, ahead of the US market average, and revenue growth is forecast at 9.6% per year. With the share price trading below analyst targets, investors are likely to view these results as continued evidence of...",
    "url": "https://finnhub.io/api/news?id=d351eb777c283ef2cb2cfd3de1cda58c70b6d53c9a5aa5dae89acfd55ea5345e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761193249,
      "headline": "Boston Scientific (BSX): Earnings Jump 37%, Profit Margins Beat Bull Case Expectations",
      "id": 137198215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (BSX) delivered standout earnings growth, with profits up 18.5% per year over the last five years and a strong 37% gain in the most recent year. Net profit margins rose to 13.5% from 12% previously. Forward-looking guidance points to annual earnings growth of 16.6%, ahead of the US market average, and revenue growth is forecast at 9.6% per year. With the share price trading below analyst targets, investors are likely to view these results as continued evidence of...",
      "url": "https://finnhub.io/api/news?id=d351eb777c283ef2cb2cfd3de1cda58c70b6d53c9a5aa5dae89acfd55ea5345e"
    }
  },
  {
    "ts": null,
    "headline": "BTIG Reiterates Boston Scientific (BSX) Buy Recommendation",
    "summary": "BTIG Reiterates Boston Scientific (BSX) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=67ab23aa5d6c53ba61afb5c1622067433322925417b5029ae3daf7edf087e93a",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761177971,
      "headline": "BTIG Reiterates Boston Scientific (BSX) Buy Recommendation",
      "id": 137193310,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=67ab23aa5d6c53ba61afb5c1622067433322925417b5029ae3daf7edf087e93a"
    }
  }
]